Glass containers for storing pharmaceutical compositions

US12186267B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12186267-B2
Application numberUS-202318310956-A
CountryUS
Kind codeB2
Filing dateMay 2, 2023
Priority dateSep 30, 2021
Publication dateJan 7, 2025
Grant dateJan 7, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

First claim

Opening claim text (preview).

What is claimed is: 1. A glass pharmaceutical vial comprising: a glass body comprising a sidewall enclosing an interior volume and an outer diameter D, wherein: the outer diameter D of the glass body is greater than or equal to 84% and less than or equal to 116% of a diameter d 1 of a glass vial of size designation X as defined by ISO 8362-1:2018, wherein X is a smallest size designation of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R, as defined by ISO 8362-1:2018, for which 116% of the diameter d 1 is greater than or equal to D; the sidewall of the glass pharmaceutical vial comprises an average wall thickness T i that is less than or equal to 0.85*s 1 , wherein s 1 is a wall thickness of the glass vial of size designation X as defined by ISO 8362-1:2018; and the glass pharmaceutical vial comprises an external organic coating and a cold storage factor of at least 2.25, as determined in accordance with a Freeze-Thaw Test. 2. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a compliance factor of at least 1.75, as determined in accordance with a Vial Compliance Test. 3. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a horizontal strength factor of at least 1.5, as determined in accordance with Horizontal Compression Test. 4. The glass pharmaceutical vial of claim 1 , wherein the external organic coating is an organic coating having a thickness greater than or equal to 20 nm and less than or equal to 40 nm. 5. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a breakage factor of at least 50, as determined in accordance with a Pendulum Impact Test. 6. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial is formed from a Type I, Class B glass according to ASTM Standard E438-92. 7. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial is formed from an aluminosilicate glass composition. 8. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in a mass of glass used to make the glass pharmaceutical vial of greater than or equal to 10%. 9. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in an amount of energy used to convert the glass pharmaceutical vial from stock glass tubing of greater than or equal to 5%. 10. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in an amount of CO 2 emitted to produce the glass pharmaceutical vial of greater than or equal to 5%. 11. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in an amount of energy used to separate the glass pharmaceutical vial from stock glass tubing of greater than or equal to 20%. 12. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial has a Type 1 chemical durability according to USP <660>. 13. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a Dynamic Impact Factor of less than 0.9, as determined in accordance with a Dynamic Impact Test. 14. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a FWHM Factor of at least 1.2, as determined in accordance with a Dynamic Impact Test. 15. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises: a Dynamic Impact Factor of less than 0.9 as determined in accordance with a Dynamic Impact Test; and a FWHM Factor of at least 1.2 as determined in accordance with the Dynamic Impact Test. 16. The glass pharmaceutical vial of claim 1 , further comprising: a shoulder extending from the sidewall; a neck extending from the shoulder; and a flange extending from the neck, the flange comprising: an underside surface extending from the neck; and an outer surface extending from the underside surface and being radially recessed inwardly thereby defining a cutout portion of the flange.

Assignees

Inventors

Classifications

  • consisting mainly of polymeric materials (B65D23/0828 takes precedence) · CPC title

  • A61J1/1468Primary

    Containers characterised by specific material properties · CPC title

  • A61J1/06Primary

    Ampoules or carpules (syringe ampoules or carpules A61M5/28) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12186267B2 cover?
Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, a…
Who is the assignee on this patent?
Corning Inc
What technology area does this patent fall under?
Primary CPC classification A61J1/1468. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).